Adverse event reporting information can be found at the bottom of the page

Maintenance and Reliever Therapy (MART)

You are here: / / MART

MART at GINA treatment steps 3-5 with WockAIR® 160/4.5mcg offers:

  • Significant reduction in risk of asthma exacerbations compared to SABA containing regimens3
  • A simple SABA free inhaled regimen– your patients will only need one inhaler for MART.1,2
  • A licensed low dose ICS/formoterol combination inhaler aligned with NICE Guidelines for use of MART7
  • A patient and carbon friendly device4,5
  • A 32% lower NHS list price versus Symbicort6
Clinical Evidence for AIR

MART allows the patient to use the same ICS/formoterol inhaler for regular maintenance therapy as well as reliever therapy, and eliminates the need for a short-acting beta agonist (known as SABA).1

NICE Guidelines state that MART should be offered to people aged 12 and over with asthma that is not controlled on a low-dose ICS/formoterol combination inhaler used only as needed.[7]

MART can only be used with combination ICS/formoterol inhalers. Combinations of ICS with non-formoterol LABAs or ICS-SABA cannot be used with MART.1

In clinical studies budesonide/formoterol maintenance and reliever therapy provided statistically significant and clinically meaningful reductions in severe exacerbations compared to ICS/formoterol with SABA reliever.1

MART

Dosing

With MART in asthma, patients take a daily maintenance dose of WockAIR® and in addition also take WockAIR® as needed in response to symptoms, meaning both controller and reliever in one handy device.¹

MART administration applies to the 160/4.5 inhaler only. Patients should be advised always to have WockAIR® available for rescue use.

Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

Adverse events should also be reported to Wockhardt UK. Please contact us or email us at drug.safety@wockhardt.co.uk

REFERENCES

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Updated July 2023. Available from ginasthma.org

2. WockAIR® 160/4.5mcg Summary of Product Characteristics

3. Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA 2018; 319: 1485–1496.

4. Virchow JC, Weuthen T, Harmer QJ, Jones S. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study. Expert Opin Drug Deliv. 2014;11(12):1849–57

5. Janson C, et al. Thorax 2020;75:82–84. doi:10.1136/thoraxjnl-2019-213744. Carbon footprint impact of the choice of inhalers for asthma and COPD

6. MIMS May 2025

7. NICE Guideline: Asthma: Diagnosis, monitoring and chronic asthma management 27 Nov 2024 Available at www.nice.org/guidance/ng245

ABBREVIATIONS

AIR-anti-inflammatory reliever; MART – Maintenance and Reliever Therapy; GINA-Global Initiative for Asthma; ICS- inhaled corticosteroid; SABA -short acting beta agonist; RCT- randomised controlled trial; LABA- long acting beta agonist.

This site is intended for UK Healthcare Professionals.
Contact Us | Cookies and Privacy Policy | Terms of and Conditions of Use | Sitemap | PIL | Pharmacovigilance Privacy Notice
Job code: AIR06/25 July 2025